Dynavax Technologies Stock Price, News & Analysis (NASDAQ:DVAX)

$17.75 -0.85 (-4.57 %)
(As of 12/13/2017 01:49 PM ET)
Previous Close$18.60
Today's Range$17.65 - $18.67
52-Week Range$3.70 - $24.45
Volume1.59 million shs
Average Volume1.86 million shs
Market Capitalization$1.13 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.31

About Dynavax Technologies (NASDAQ:DVAX)

Dynavax Technologies logoDynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma. Its products include HEPLISAV-B, AZD1419, SD-101, DV281, DV230F and DV1001. HEPLISAV-B is an investigational adult hepatitis B vaccine. AZD1419 is being developed for the treatment of asthma. SD-101 is an investigational TLR9 agonist designed to elicit a potent and focused immune response to cancer. DV281 is an investigational TLR9 agonist designed specifically for focused delivery to primary lung tumors and lung metastases. DV230F is indicated for the treatment of Liver Tumors. DV1001 targets TLR 7 and 8 agonist for multiple malignancies. DV230F and DV1001 are in pre-clinical stage of development.

Receive DVAX News and Ratings via Email

Sign-up to receive the latest news and ratings for DVAX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:DVAX
CUSIP26815810
Phone510-848-5100

Debt

Debt-to-Equity RatioN/A
Current Ratio15.30%
Quick Ratio15.30%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$11.04 million
Price / Sales97.43
Cash FlowN/A
Price / CashN/A
Book Value$2.32 per share
Price / Book7.65

Profitability

Trailing EPS($1.95)
Net Income$-112,440,000.00
Net Margins-1,177.60%
Return on Equity-65.97%
Return on Assets-59.47%

Miscellaneous

Employees251
Outstanding Shares60,600,000

Dynavax Technologies (NASDAQ:DVAX) Frequently Asked Questions

What is Dynavax Technologies' stock symbol?

Dynavax Technologies trades on the NASDAQ under the ticker symbol "DVAX."

How were Dynavax Technologies' earnings last quarter?

Dynavax Technologies Corporation (NASDAQ:DVAX) released its quarterly earnings data on Friday, November, 3rd. The biopharmaceutical company reported ($0.38) EPS for the quarter, topping analysts' consensus estimates of ($0.53) by $0.15. The biopharmaceutical company had revenue of $0.05 million for the quarter, compared to the consensus estimate of $0.28 million. Dynavax Technologies had a negative return on equity of 65.97% and a negative net margin of 1,177.60%. The firm's revenue was down 68.8% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.90) earnings per share. View Dynavax Technologies' Earnings History.

When will Dynavax Technologies make its next earnings announcement?

Dynavax Technologies is scheduled to release their next quarterly earnings announcement on Monday, March, 12th 2018. View Earnings Estimates for Dynavax Technologies.

Where is Dynavax Technologies' stock going? Where will Dynavax Technologies' stock price be in 2017?

5 equities research analysts have issued 12-month price objectives for Dynavax Technologies' shares. Their forecasts range from $25.00 to $30.00. On average, they expect Dynavax Technologies' stock price to reach $28.00 in the next twelve months. View Analyst Ratings for Dynavax Technologies.

What are Wall Street analysts saying about Dynavax Technologies stock?

Here are some recent quotes from research analysts about Dynavax Technologies stock:

  • 1. Cantor Fitzgerald analysts commented, "Launch in 1Q18. Dynavax anticipates launching the product in 1Q18 and previously noted drug supply of over 250,000 vials of product available by the time of launch, with an additional 750,000 vials worth of raw material. In 2H18, Dynavax expects its Dusseldorf plant to manufacture drug supply. We estimate the current supply will support commercialization for over two years, providing ample runway to produce additional supply." (11/9/2017)
  • 2. Cowen Inc analysts commented, "Dynavax reported a Q3 net loss of $22.1MM and ended the quarter with $192MM in." (11/3/2017)
  • 3. According to Zacks Investment Research, "Dynavax Technologies discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Dynavax's clinical development programs are based on immunostimulatory sequences which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation. " (8/4/2017)

Who are some of Dynavax Technologies' key competitors?

Who are Dynavax Technologies' key executives?

Dynavax Technologies' management team includes the folowing people:

  • Arnold L. Oronsky Ph.D., Independent Chairman of the Board (Age 77)
  • Eddie Gray, Chief Executive Officer, Director (Age 58)
  • Michael S. Ostrach, Chief Financial Officer, Senior Vice President, Chief Business Officer (Age 65)
  • Robert L. Coffman Ph.D., Senior Vice President, Chief Scientific Officer (Age 70)
  • David F. Novack, Senior Vice President - Operations and Quality (Age 55)
  • Robert Janssen M.D., Chief Medical Officer, Vice President - Clinical Development and Regulatory Affairs (Age 63)
  • Laura A. Brege, Independent Director (Age 59)
  • Francis R. Cano Ph.D., Independent Director (Age 70)
  • Dennis A. Carson M.D., Independent Director (Age 70)
  • Daniel L. Kisner M.D., Independent Director (Age 70)

Who owns Dynavax Technologies stock?

Dynavax Technologies' stock is owned by a number of of retail and institutional investors. Top institutional investors include GMT Capital Corp (5.05%), Senvest Management LLC (1.97%), Kornitzer Capital Management Inc. KS (2.03%), Point72 Asset Management L.P. (1.83%), C WorldWide Group Holding A S (1.36%) and Ameriprise Financial Inc. (0.99%). Company insiders that own Dynavax Technologies stock include Eddie Gray and Robert Janssen. View Institutional Ownership Trends for Dynavax Technologies.

Who sold Dynavax Technologies stock? Who is selling Dynavax Technologies stock?

Dynavax Technologies' stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Senvest Management LLC, Ameriprise Financial Inc., Candriam Luxembourg S.C.A., JPMorgan Chase & Co., Allianz Asset Management GmbH, Kornitzer Capital Management Inc. KS and Russell Investments Group Ltd.. View Insider Buying and Selling for Dynavax Technologies.

Who bought Dynavax Technologies stock? Who is buying Dynavax Technologies stock?

Dynavax Technologies' stock was purchased by a variety of institutional investors in the last quarter, including EAM Investors LLC, C WorldWide Group Holding A S, Artal Group S.A., First Republic Investment Management Inc., Bank of New York Mellon Corp, Nationwide Fund Advisors, Crawford Lake Capital Management LLC and Schwab Charles Investment Management Inc.. Company insiders that have bought Dynavax Technologies stock in the last two years include Eddie Gray and Robert Janssen. View Insider Buying and Selling for Dynavax Technologies.

How do I buy Dynavax Technologies stock?

Shares of Dynavax Technologies can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Dynavax Technologies' stock price today?

One share of Dynavax Technologies stock can currently be purchased for approximately $17.75.

How big of a company is Dynavax Technologies?

Dynavax Technologies has a market capitalization of $1.13 billion and generates $11.04 million in revenue each year. The biopharmaceutical company earns $-112,440,000.00 in net income (profit) each year or ($1.95) on an earnings per share basis. Dynavax Technologies employs 251 workers across the globe.

How can I contact Dynavax Technologies?

Dynavax Technologies' mailing address is 2929 SEVENTH STREET SUITE 100, BERKELEY CA, 94710. The biopharmaceutical company can be reached via phone at 510-848-5100 or via email at [email protected]


MarketBeat Community Rating for Dynavax Technologies (DVAX)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  194 (Vote Outperform)
Underperform Votes:  181 (Vote Underperform)
Total Votes:  375
MarketBeat's community ratings are surveys of what our community members think about Dynavax Technologies and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Dynavax Technologies (NASDAQ:DVAX) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.002.50
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $26.00$26.00$25.80$21.40
Price Target Upside: 29.68% upside29.68% upside43.34% upside296.33% upside

Dynavax Technologies (NASDAQ:DVAX) Consensus Price Target History

Price Target History for Dynavax Technologies (NASDAQ:DVAX)

Dynavax Technologies (NASDAQ:DVAX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/9/2017Cantor FitzgeraldBoost Price TargetOverweight$24.00 -> $25.00N/AView Rating Details
11/3/2017CowenReiterated RatingBuy$30.00N/AView Rating Details
9/25/2017Royal Bank of CanadaReiterated RatingOutperform -> Outperform$26.00 -> $28.00HighView Rating Details
8/9/2017William BlairReiterated RatingOutperform$30.00HighView Rating Details
7/31/2017J P Morgan Chase & CoUpgradeNeutral -> Overweight$6.00 -> $27.00HighView Rating Details
9/2/2016S&P Equity ResearchBoost Price Target$11.28 -> $16.01N/AView Rating Details
(Data available from 12/13/2015 forward)

Earnings

Dynavax Technologies (NASDAQ:DVAX) Earnings History and Estimates Chart

Earnings by Quarter for Dynavax Technologies (NASDAQ:DVAX)

Dynavax Technologies (NASDAQ DVAX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/12/2018        
11/3/2017Q3 2017($0.53)($0.38)$0.28 million$0.05 millionViewN/AView Earnings Details
8/2/2017Q2 2017($0.50)($0.41)$0.15 million$0.11 millionViewN/AView Earnings Details
5/8/2017Q1 2017($0.60)($0.60)$0.75 million$0.15 millionViewN/AView Earnings Details
3/13/2017Q4 2016($0.85)($0.56)$2.90 million$7.30 millionViewN/AView Earnings Details
11/7/2016Q3($0.75)($0.90)$2.44 million$0.20 millionViewN/AView Earnings Details
8/5/2016Q2($0.68)($0.75)$1.58 million$2.65 millionViewN/AView Earnings Details
5/9/2016Q1($0.63)($0.70)$627.00 million$942.00 millionViewN/AView Earnings Details
3/8/2016Q4($0.75)($0.70)$1.15 million$0.69 millionViewN/AView Earnings Details
11/5/2015Q3($0.78)($0.82)$1.65 million$1.20 millionViewN/AView Earnings Details
8/7/2015Q2($1.00)($0.80)$3.05 million$1.55 millionViewN/AView Earnings Details
5/7/2015Q1 2015($0.95)($0.97)$1.26 million$0.63 millionViewN/AView Earnings Details
3/5/2015Q4 2014($1.06)($0.85)$2.15 million$2.28 millionViewN/AView Earnings Details
11/5/2014Q314($0.09)($0.11)$2.50 million$2.21 millionViewN/AView Earnings Details
8/7/2014Q214($0.06)($0.09)$2.26 million$3.05 millionViewN/AView Earnings Details
5/5/2014Q1 2014($0.06)($0.05)$4.22 million$3.50 millionViewN/AView Earnings Details
3/10/2014Q413($0.07)($0.09)$1.56 million$2.80 millionViewN/AView Earnings Details
11/7/2013Q313($0.10)($0.09)$1.83 million$2.93 millionViewN/AView Earnings Details
7/29/2013Q2 2013($0.10)($0.09)$2.91 million$3.40 millionViewN/AView Earnings Details
5/6/2013Q113($0.11)($0.11)$2.40 million$2.10 millionViewN/AView Earnings Details
3/1/2013Q4 2012($0.11)$11.40 million$1.80 millionViewN/AView Earnings Details
11/1/2012Q312($0.08)($0.10)$5.00 million$2.90 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Dynavax Technologies (NASDAQ:DVAX) Earnings Estimates

2017 EPS Consensus Estimate: ($1.57)
2018 EPS Consensus Estimate: ($0.58)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.46)($0.46)($0.46)
Q2 20171($0.44)($0.44)($0.44)
Q3 20171($0.32)($0.32)($0.32)
Q4 20171($0.35)($0.35)($0.35)
Q1 20181($0.25)($0.25)($0.25)
Q2 20181($0.19)($0.19)($0.19)
Q3 20181($0.12)($0.12)($0.12)
Q4 20181($0.02)($0.02)($0.02)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Dynavax Technologies (NASDAQ:DVAX)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Dynavax Technologies (NASDAQ DVAX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 2.90%
Institutional Ownership Percentage: 70.61%
Insider Trades by Quarter for Dynavax Technologies (NASDAQ:DVAX)
Institutional Ownership by Quarter for Dynavax Technologies (NASDAQ:DVAX)

Dynavax Technologies (NASDAQ DVAX) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/24/2017Robert JanssenVPBuy6,000$4.04$24,240.00View SEC Filing  
6/28/2016Robert JanssenVPBuy1,452$13.68$19,863.36View SEC Filing  
5/20/2016Eddie GrayCEOBuy2,750$15.57$42,817.50View SEC Filing  
5/12/2016Robert JanssenVPBuy1,000$15.12$15,120.00View SEC Filing  
8/14/2014Eddie GrayCEOBuy25,000$1.49$37,250.00View SEC Filing  
10/30/2013Peggy V PhillipsDirectorBuy93,023$1.08$100,464.84View SEC Filing  
9/14/2012Jennifer LewVPSell18,750$4.53$84,937.50View SEC Filing  
9/13/2012Robert CoffmanVPSell8,000$4.52$36,160.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Dynavax Technologies (NASDAQ DVAX) News Headlines

Source:
DateHeadline
BidaskClub Downgrades Dynavax Technologies (DVAX) to HoldBidaskClub Downgrades Dynavax Technologies (DVAX) to Hold
www.americanbankingnews.com - December 10 at 3:46 PM
Dynavax Technologies Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)Dynavax Technologies Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
finance.yahoo.com - December 5 at 5:16 PM
$37.77 Million in Sales Expected for Dynavax Technologies Corporation (DVAX) This Quarter$37.77 Million in Sales Expected for Dynavax Technologies Corporation (DVAX) This Quarter
www.americanbankingnews.com - December 5 at 9:06 AM
Dynavax Technologies (DVAX) Downgraded to Sell at ValuEngineDynavax Technologies (DVAX) Downgraded to Sell at ValuEngine
www.americanbankingnews.com - December 3 at 3:46 PM
Zacks: Analysts Expect Dynavax Technologies Corporation (DVAX) Will Post Earnings of $0.30 Per ShareZacks: Analysts Expect Dynavax Technologies Corporation (DVAX) Will Post Earnings of $0.30 Per Share
www.americanbankingnews.com - December 3 at 5:36 AM
Dynavax Technologies Corporation (DVAX) Receives Average Rating of "Buy" from BrokeragesDynavax Technologies Corporation (DVAX) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - December 3 at 2:20 AM
Dynavax Technologies CorpDynavax Technologies Corp
www.bloomberg.com - December 2 at 5:09 PM
Dynavax Shares A Glimpse Of The Future - Seeking AlphaDynavax Shares A Glimpse Of The Future - Seeking Alpha
seekingalpha.com - December 2 at 9:49 AM
Report: Exploring Fundamental Drivers Behind Starbucks, Home Depot, Kroger, Dynavax Technologies, Kratos Defense & Security Solutions, and Medtronic — New Horizons, Emerging Trends, and Upcoming DevelopmentsReport: Exploring Fundamental Drivers Behind Starbucks, Home Depot, Kroger, Dynavax Technologies, Kratos Defense & Security Solutions, and Medtronic — New Horizons, Emerging Trends, and Upcoming Developments
finance.yahoo.com - November 28 at 8:46 AM
Dynavax to Present at the Evercore ISI Biopharma Catalyst/Deep Dive ConferenceDynavax to Present at the Evercore ISI Biopharma Catalyst/Deep Dive Conference
finance.yahoo.com - November 27 at 6:00 PM
Dynavax: Now The Fun Begins - Seeking AlphaDynavax: Now The Fun Begins - Seeking Alpha
seekingalpha.com - November 22 at 6:50 PM
Technical Snapshots for These Biotech Stocks -- Dynavax Technologies, Keryx Biopharma, Moleculin Biotech, and TG TherapeuticsTechnical Snapshots for These Biotech Stocks -- Dynavax Technologies, Keryx Biopharma, Moleculin Biotech, and TG Therapeutics
www.bizjournals.com - November 17 at 12:51 PM
Equities Analysts Issue Forecasts for Dynavax Technologies Corporations FY2017 Earnings (DVAX)Equities Analysts Issue Forecasts for Dynavax Technologies Corporation's FY2017 Earnings (DVAX)
www.americanbankingnews.com - November 15 at 6:58 AM
Dynavax Stock Under Selling Pressure (NASDAQ:DVAX) | Benzinga - BenzingaDynavax Stock Under Selling Pressure (NASDAQ:DVAX) | Benzinga - Benzinga
www.benzinga.com - November 15 at 4:33 AM
Dynavax Technologies Corporation (DVAX) Expected to Announce Earnings of $0.30 Per ShareDynavax Technologies Corporation (DVAX) Expected to Announce Earnings of $0.30 Per Share
www.americanbankingnews.com - November 14 at 7:08 PM
Dynavax: Heplisav-B Approved, What Was Said On The Conference Call And What It Means - Seeking AlphaDynavax: Heplisav-B Approved, What Was Said On The Conference Call And What It Means - Seeking Alpha
seekingalpha.com - November 13 at 6:41 PM
Cowen Anticipates Dynavax’s Now-Approved Heplisav Will Lead the HBV Vaccine MarketCowen Anticipates Dynavax’s Now-Approved Heplisav Will Lead the HBV Vaccine Market
finance.yahoo.com - November 13 at 11:49 AM
Today’s Research Reports on Stocks to Watch: Dynavax Technologies and Puma BiotechnologyToday’s Research Reports on Stocks to Watch: Dynavax Technologies and Puma Biotechnology
finance.yahoo.com - November 13 at 11:49 AM
Dynavax stock surges 18% on hepatitis B vaccine approval - MarketWatchDynavax stock surges 18% on hepatitis B vaccine approval - MarketWatch
www.marketwatch.com - November 12 at 5:46 PM
Its Not Too Late to Buy Dynavax Stock After Its Hepatitis B Vaccine Approval - Motley FoolIt's Not Too Late to Buy Dynavax Stock After Its Hepatitis B Vaccine Approval - Motley Fool
www.fool.com - November 11 at 10:58 PM
At Long Last, Dynavax Wins FDA Approval For HeplisavAt Long Last, Dynavax Wins FDA Approval For Heplisav
finance.yahoo.com - November 11 at 5:57 PM
Dynavax Triumphs With Heplisav-B: Now What? - Seeking AlphaDynavax Triumphs With Heplisav-B: Now What? - Seeking Alpha
seekingalpha.com - November 10 at 6:35 PM
Dynavax Stock Climbs On HEPLISAV-Bs Approval By FDA For Hepatitis B In AdultsDynavax Stock Climbs On HEPLISAV-B's Approval By FDA For Hepatitis B In Adults
www.nasdaq.com - November 10 at 11:09 AM
Dynavax (DVAX) Reports FDA Approval of HEPLISAV-B for Prevention of Hepatitis B in AdultsDynavax (DVAX) Reports FDA Approval of HEPLISAV-B for Prevention of Hepatitis B in Adults
www.streetinsider.com - November 10 at 11:09 AM
Options Traders Expect Huge Moves in Dynavax (DVAX) StockOptions Traders Expect Huge Moves in Dynavax (DVAX) Stock
finance.yahoo.com - November 10 at 11:09 AM
Dynavax Announces FDA Approval of HEPLISAV-B(TM) for Prevention of Hepatitis B in AdultsDynavax Announces FDA Approval of HEPLISAV-B(TM) for Prevention of Hepatitis B in Adults
finance.yahoo.com - November 10 at 11:09 AM
Dynavax Technologies Corporation’s (DVAX) Hepatitis B Vaccine Wins FDA ApprovalDynavax Technologies Corporation’s (DVAX) Hepatitis B Vaccine Wins FDA Approval
finance.yahoo.com - November 10 at 11:09 AM
Third time’s the charm: Dynavax shares rocket 18% on hepatitis B vaccine approvalThird time’s the charm: Dynavax shares rocket 18% on hepatitis B vaccine approval
finance.yahoo.com - November 10 at 11:09 AM
Dynavax Technologies Corporation (DVAX) Rating Reiterated by Cantor FitzgeraldDynavax Technologies Corporation (DVAX) Rating Reiterated by Cantor Fitzgerald
www.americanbankingnews.com - November 9 at 11:38 PM
ETFs with exposure to Dynavax Technologies Corp. : November 8, 2017ETFs with exposure to Dynavax Technologies Corp. : November 8, 2017
finance.yahoo.com - November 8 at 9:52 PM
Jim Cramer Shares His Thoughts On Dynavax, Whiting Petroleum ... - BenzingaJim Cramer Shares His Thoughts On Dynavax, Whiting Petroleum ... - Benzinga
www.benzinga.com - November 8 at 4:52 PM
Dynavax Awaits FDA Verdict On Hepatitis B Vaccine - BenzingaDynavax Awaits FDA Verdict On Hepatitis B Vaccine - Benzinga
www.benzinga.com - November 8 at 4:52 PM
Dynavax Technologies Corp. breached its 50 day moving average in a Bullish Manner : DVAX-US : November 8, 2017Dynavax Technologies Corp. breached its 50 day moving average in a Bullish Manner : DVAX-US : November 8, 2017
finance.yahoo.com - November 8 at 4:52 PM
Dynavax Awaits FDA Verdict On Hepatitis B VaccineDynavax Awaits FDA Verdict On Hepatitis B Vaccine
feeds.benzinga.com - November 8 at 3:54 PM
FY2017 EPS Estimates for Dynavax Technologies Corporation (DVAX) Lifted by William BlairFY2017 EPS Estimates for Dynavax Technologies Corporation (DVAX) Lifted by William Blair
www.americanbankingnews.com - November 8 at 9:38 AM
Dynavax Reaches The Finish Line: Triumph Or Stumble? - Seeking AlphaDynavax Reaches The Finish Line: Triumph Or Stumble? - Seeking Alpha
seekingalpha.com - November 8 at 3:01 AM
Dynavaxs Binary Moment - Seeking AlphaDynavax's Binary Moment - Seeking Alpha
seekingalpha.com - November 8 at 3:01 AM
Dynavax Technologies Corp. :DVAX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 7, 2017Dynavax Technologies Corp. :DVAX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 7, 2017
finance.yahoo.com - November 8 at 3:01 AM
Dynavax Technologies Corporation (DVAX) Receives Average Recommendation of "Buy" from BrokeragesDynavax Technologies Corporation (DVAX) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - November 8 at 1:38 AM
Dynavax Technologies Corporation (DVAX) Earns "Buy" Rating from Cowen and CompanyDynavax Technologies Corporation (DVAX) Earns "Buy" Rating from Cowen and Company
www.americanbankingnews.com - November 4 at 7:29 PM
Dynavax Technologies Corporation (DVAX) Announces  Earnings Results, Beats Estimates By $0.15 EPSDynavax Technologies Corporation (DVAX) Announces Earnings Results, Beats Estimates By $0.15 EPS
www.americanbankingnews.com - November 4 at 1:44 PM
Dynavax Reports Third Quarter 2017 Financial ResultsDynavax Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 3 at 1:26 PM
Dynavax Technologies reports 3Q lossDynavax Technologies reports 3Q loss
finance.yahoo.com - November 3 at 1:26 PM
5 Biotech and Pharma Stocks with Key FDA Catalysts this November5 Biotech and Pharma Stocks with Key FDA Catalysts this November
finance.yahoo.com - November 2 at 7:11 PM
Is There Now An Opportunity In Dynavax Technologies Corporation (DVAX)?Is There Now An Opportunity In Dynavax Technologies Corporation (DVAX)?
finance.yahoo.com - November 1 at 7:03 PM
Dynavax Technologies Corporation (DVAX) to Release Earnings on MondayDynavax Technologies Corporation (DVAX) to Release Earnings on Monday
www.americanbankingnews.com - October 30 at 5:46 AM
Dynavax Technologies Corp. – Value Analysis (NASDAQ:DVAX) : October 26, 2017Dynavax Technologies Corp. – Value Analysis (NASDAQ:DVAX) : October 26, 2017
finance.yahoo.com - October 26 at 1:44 PM
Dynavax Technologies Corp. breached its 50 day moving average in a Bullish Manner : DVAX-US : October 25, 2017Dynavax Technologies Corp. breached its 50 day moving average in a Bullish Manner : DVAX-US : October 25, 2017
finance.yahoo.com - October 25 at 7:48 PM
US vaccine panel to discuss waning effectiveness, new shotsUS vaccine panel to discuss waning effectiveness, new shots
marketbeat.com - October 24 at 3:34 PM
Commit To Buy Dynavax Technologies Corp At $10, Earn 15% Using OptionsCommit To Buy Dynavax Technologies Corp At $10, Earn 15% Using Options
www.nasdaq.com - October 23 at 6:34 PM

SEC Filings

Dynavax Technologies (NASDAQ:DVAX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Dynavax Technologies (NASDAQ:DVAX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Dynavax Technologies (NASDAQ DVAX) Stock Chart for Wednesday, December, 13, 2017

Loading chart…

This page was last updated on 12/13/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.